Skip to main content

Table 2 Laboratory findings and medication in use in evolocumab group and control group

From: Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study

 

Evolocumab (n = 85)

Control (n = 85)

p value between groups

Baseline

Follow-up

p

Baseline

Follow-up

p

Baseline

Follow-up

Laboratory findingsa

        

 TC (mmol/L)

4.56 (2.78, 6.89)

3.32 (2.18, 4.37)

 < 0.001

4.48 (2.98, 6.69)

3.81 (2.62, 5.89)

0.052

0.914

0.016

 HDL-C (mmol/L)

1.38 (1.23, 1.65)

1.41 (1.55, 1.80)

0.869

1.32 (1.11, 1.52)

1.35 (1.21, 1.62)

0.301

0.622

0.099

 LDL-C (mmol/L)

3.34 (2.53, 4.14)

2.02 (1.26, 2.78)

 < 0.001

3.23 (2.54, 4.02)

3.18 (2.63, 3.79)

0.904

0.666

 < 0.001

 TG (mmol/L)

1.56 (1.23, 2.11)

1.38 (1.13, 1.58)

0.005

1.47 (1.28, 1.98)

1.33 (1.13, 1.73)

0.088

0.922

0.499

 Lp(a) (mg/dL)

18.9 (13.2, 27.2)

12.1 (5.6, 21.8)

0.002

17.6 (12.6, 27.5)

18.9 (9.5, 28.2)

0.918

0.650

0.001

 HbA1c (%)

6.6 (5.9, 7.3)

6.8 (6.1, 7.4)

0.473

6.7 (6.0, 7.4)

6.9 (6.1, 7.4)

0.472

0.376

0.443

 CRP (mg/L)

3.1 (1.9, 3.9)

2.9 (2.5, 3.2)

0.531

2.8 (1.9, 3.4)

2.9 (2.4, 3.5)

0.543

0.284

0.867

Medication in use, n (%)

        

 ACEI/ARB

49 (57.6)

51 (60.0)

0.876

47 (55.2)

50 (58.8)

0.756

0.877

1.000

 β-Blocker

33 (38.8)

35 (41.1)

0.875

35 (41.1)

39 (45.9)

0.642

0.875

0.643

 Nitrates

29 (34.1)

31 (36.5)

0.873

32 (37.6)

36 (42.3)

0.638

0.749

0.530

  1. Unless otherwise specified, data are numbers of patients, with percentages in parentheses
  2. ACEI, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin receptor blocker; CRP, C-reactive protein; HbA1c, Hemoglobin A1c; HDL-C, High density lipoprotein cholesterol; LDL-C, Low density lipoprotein cholesterol; Lp(a), Lipoprotein(a); TC, Total cholesterol; TG, Triglyceride
  3. aNumbers are medians, with interquartile ranges in parentheses
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840